Imagine compressing a decade of research into mere weeks or turning a failure rate of 90% in clinical drug development on its head. That's exactly what's on the horizon with the incorporation of artificial intelligence (AI) in the realm of drug discovery, and the person leading this charge is none other than Dr. Max Jakobs, CEO and co-founder of DeepMirror. Prepare to be blown away as we navigate the potential AI holds for revolutionizing healthcare, making it possible to sift through massive datasets with unprecedented speed and accuracy. In our exciting conversation with Dr. Jakobs, we dig into the gritty realities of drug discovery in its current state and the formidable issues researchers face without the aid of AI algorithms. Get ready to discover how AI not only hastens the drug-to-market journey but also boosts the clinical hit rates, saving ample time and a fortune in the process. Plus, we probe into the daunting challenge of FDA approval and how DeepMirror is working to dismantle the bias inherent in traditional drug development. To conclude, we delve into the groundbreaking advancements in small molecule drug discovery and how cloud-based AI is honing laboratory processes. Dr. Jakobs illustrates how DeepMirror is utilizing AI to unearth the most promising drug candidates more efficiently. We bring to light riveting customer success stories and the promising future that lies ahead with AI-based data analysis in the pharmaceutical industry. Brace yourselves for a riveting exploration of AI's impact on drug discovery and healthcare. Support the show